Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine.

Literature DB >> 8093319

Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine.

L Bertilsson, M L Dahl, F Sjöqvist, A Aberg-Wistedt, M Humble, I Johansson, E Lundqvist, M Ingelman-Sundberg.

Abstract

Entities: Chemical

Mesh：

Substances：
Debrisoquin

Year: 1993 PMID： 8093319 DOI： 10.1016/0140-6736(93)92546-6

Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321

Keyword Cloud
Cited

× No keyword cloud information.

39 in total

1. Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

Authors: K J Aitchison; J Munro; P Wright; S Smith; A J Makoff; C Sachse; P C Sham; R M Murray; D A Collier; R W Kerwin
Journal: Br J Clin Pharmacol Date: 1999-09 Impact factor: 4.335

Review 2. Science, medicine, and the future: Pharmacogenetics.

Authors: C R Wolf; G Smith; R L Smith
Journal: BMJ Date: 2000-04-08

Review 3. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Authors: Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Journal: Br J Clin Pharmacol Date: 2002-02 Impact factor: 4.335

4. Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects.

Authors: Myo-Kyoung Kim; Joo-Youn Cho; Hyeong-Seok Lim; Kyoung-Seop Hong; Jae-Yong Chung; Kyun-Seop Bae; Dal-Seok Oh; Sang-Goo Shin; Sang-Hun Lee; Dong-Ho Lee; Bumchan Min; In-Jin Jang
Journal: Eur J Clin Pharmacol Date: 2003-05-01 Impact factor: 2.953

Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine.

1. Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

Review 2. Science, medicine, and the future: Pharmacogenetics.

Review 3. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

4. Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects.

Review 5. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.

Review 6. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.

7. Toxicogenetics--cytochrome P450 microarray analysis in forensic cases focusing on morphine/codeine and diazepam.

Review 8. The Role of Metabolites of Antidepressants in the Treatment of Depression.

9. Cytochrome P4502D6 genotype does not determine response to clozapine.

10. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.